Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis

Thetis Awarded $1.9M NIH Grant to Advance TP-252 into Clinical Trials for Ulcerative Colitis
Thetis Pharmaceuticals recently received a $1.9 million fast-track Small Business Innovation Research grant from the National Institutes of Health (NIH) to help advance the development of TP-252, an investigational oral therapy for ulcerative colitis (UC), into clinical trials. TP-252 is a derivative of eicosapentaenoic acid free fatty acid (EPA-FFA), which has been shown to help reduce relapse in UC patients. EPA-FFA is naturally found in the human body and plays a critical role in the regulation of the body’s inflammatory response. TP-252 is being developed as an adjunct therapy to 5-ASA, or mesalimine, a therapy used in the maintenance and remission of UC.  5-ASA is approved by the U.S. Food and Drug Administration for UC treatment. As an add-on therapy to first-line treatment 5-ASA, TP-252 could be beneficial to UC patients by controlling the underlying inflammation and reducing the frequency and severity of disease relapses, reducing the need for more aggressive therapies and decreasing the risk of severe adverse reactions. TP-252's active compound was recently investigated in a randomized, placebo-controlled, double-blind trial (NCT02179372) in which it was shown to significantly reduce the rate of relapse of UC patients already on therapy. “TP-252 is a
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *